A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
Services
Services
Date issued
2015Journal title
ANNALS OF ONCOLOGY
Type of content
Artigo
